Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| PDS Biotechnology Corporation | PDS0101 in combination with KEYTRUDA - (VERSATILE-003) | Human papillomavirus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC) | Phase 3 | Trial Planned | Intravenous | Oncology |
| PDS Biotechnology Corporation | Interleukin-12 (IL-12/PDS01ADC) | 3rd Line Metastatic Castration Resistant Prostate Cancer | Phase 2 | Data Released | Intravenous | Oncology |
| PDS Biotechnology Corporation | PDS0101, PDS0301, and immune checkpoint inhibitor (ICI) | Human papillomavirus (HPV) 16-positive cancers | Phase 2 | Ongoing | PDS0101 subcutaneous PDS0301 intravenous immune checkpoint inhibitor intravenous | Oncology |
| PDS Biotechnology Corporation | PDS0101, M9241, and bintrafusp alfa | Human papillomavirus (HPV) associated cancers | Phase 2 | Ongoing | Intravenous | Oncology |
| PepGen Inc. | PGN-EDO51 - (CONNECT1) | Duchenne muscular dystrophy (DMD) | Phase 2 | Trial Discontinued | Intravenous | Genetic Disorder |
| PepGen Inc. | PGN-EDO51 - (CONNECT2) | Duchenne muscular dystrophy (DMD) | Phase 2 | Clinical Hold | intravenous | Genetic Disorder |
| Petros Pharmaceuticals Inc. | H-100 | Peyronie's disease | NDA Filing | Topical | Orthopedic | |
| Pfizer Inc. | HYMPAVZI (marstacimab) | Hemophilia A or B | PDUFA priority review | Ongoing | Intravenous | Hematology |
